LD-2 disclosure · 1st Quarter - Report
ABBVIE INC.
via ABBVIE, INC.
Client
- Name
- ABBVIE INC.
- Location
- District of Columbia · United States of America
Registrant
- Firm
- ABBVIE, INC.
- Description
- Biopharmaceutical company
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
6 issuesCopyright/Patent/Trademark
S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property
LobbyistsSTEPHEN SCANGO · DANIEL BACHNER · DORCAS ADEKUNLE · CRYSTAL RILEY · RACHEL DERBY
TargetedSENATE · HOUSE OF REPRESENTATIVES
Health Issues
S. 864, HELP Copays Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act S. 2903, Safe Step Act H.R. 5509, Safe Step Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Issues related to data privacy Issues related to Hepatitis C elimination Issues related to FDA communications
LobbyistsSTEPHEN SCANGO · DANIEL BACHNER · DORCAS ADEKUNLE · CRYSTAL RILEY · RACHEL DERBY
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment